There are no discussions yet.

  • Disease Description


    Type 2 diabetes mellitus is a disorder affecting the way your body uses glucose (sugar). Cells in your body need sugar to work normally and sugar gets into the cells with the help of the hormone called insulin. Without enough insulin, or if the body stops responding to insulin, sugar builds up in the blood.[1]


    In type 2 diabetes mellitus, the pancreas does not make enough insulin, the body becomes resistant to normal or even high levels of insulin, or both. This causes high blood glucose (blood sugar) levels, which can cause serious problems if untreated.[1]


    Type 2 diabetes is a medical condition that requires regular monitoring and treatment throughout your life. Fortunately, with proper treatment one can keep blood sugar levels close to normal and minimize the risk of developing complications.[1]


    Prevalence


    In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. Diabetes remains the 7th leading cause of death in the United States in 2010, with 69,071 death certificates listing it as the underlying cause of death, and a total of 234,051 death certificates listing diabetes as an underlying or contributing cause of death. In the United States, Canada, and Europe, about 90 percent of all people with diabetes have type 2 diabetes.[2]


    Current Treatment Options


    Treatment includes lifestyle changes, self-care measures, and sometimes medications.A number of oral medicines (pills) are available to treat type 2 diabetes. [2]


    Metformin — Most people who are newly diagnosed with type 2 diabetes will immediately begin a medicine called metformin (Glucophage, Glumetza, Riomet, Fortamet). Metformin improves how your body responds to insulin to reduce high blood sugar levels.[2]


    Insulin — In the past, insulin treatment was reserved for patients with type 2 diabetes whose blood sugars were not controlled with oral medicines and lifestyle changes. However, there is increasing evidence that using insulin at earlier stages may improve overall diabetes control and help to preserve the pancreas's ability to make insulin.[2]


    There are a number of additional medications on the market. You should consult with your health care provider to see which medications are right for you.


    Evidence for and Proposed Mechanism for Cannabinoid Therapies


    The study of the role of the endocannabinoids and their receptors in food intake and energy balance led, only little more than a decade after the identification of the endocannabinoid signaling system, to the development of several new therapeutic drugs. However due to unwanted side effects these drugs were eventually removed from the market.[3]


    Rather than global obesity, often associated with depressive disorders, the indication novel cannabinoid compounds, as well as of other strategies aiming at reducing endocannabinoid overactivity, should be instead for those metabolic dysfunctions that are associated with abdominal obesity. For example, the administration of second-generation CB1 receptor antagonists to moderately obese patients is likely to improve considerably the benefit/risk ratio of these compounds and result in long-term beneficial outcomes on type 2 diabetes.[3]


    1) UpToDate online resource


    2) American Diabetes Association


    3) Mechoulam et al. Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes

  • Category
    Critical Ailments
  • Created
    Thursday, 16 March 2017
  • Group admin
    CBIS

American States University

 CSi_Updates_Outline2.jpgDrug Valuation Image3


 

 Recent GBXI News:

June 22, 2023, GBX International Group, Inc., (OTC: GBXI)
Breaking Cancer Barriers; Investments in Low-Cost, Harvard Award-Winning, Effective Cancer Killing Drugs Now; GBXI Proceeds to Raise $1 Million to Fast-Track its' Success, Cancer Drug Valuations, Access for Patients, Full Company Audit, and Accelerate the Trading of the CSi-Spinout Shares

 

May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets


April 21, 2023, GBX International Group, Inc., (OTC: GBXI)

HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans 



Harvard GHC Award RCD 2018

 

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

 

Click here to review the Report:

Frontiers Capture
1mmStrong July 8 Court UPDATE Brochure Image

Sac Court Capture

Case No. 2:17-CV-02271-KJM-JDP



Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB
 



Observational Studies

PART

Notifications

Activity Stream

I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever... Show more

Raymond C. Dabney Raymond C. Dabney Great questions as usual Francis, some a bit over the line comments and questions, but I get it.

"We Own everything we speak about Owning,...
Show more
7 days ago
loader
loader
Attachment
Raymond C. Dabney Raymond C. Dabney Everything has it's Priority. Not being sick anymore was Priority Number 1.

Now that I'm past that NASTY Sickness phase we can...
Show more
7 days ago
loader
loader
Attachment

Hi Raymond,

Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:

On November 8, 2023; Capizate, Inc. (a 3rd party entity)...
Show more

Francis Cormier Thank you Raymond for your response. Glad to hear that you are on the mend. Best Regards, Francis - looking forward to future updates. 2 months ago
loader
loader
Attachment
Raymond C. Dabney You're welcome and Thank you Francis! It's been a Battle, that's for sure! Playing catch up with everyone responding to the Legacy Drug Ownership... Show more 2 months ago
loader
loader
Attachment
Raymond C. Dabney Thanks for reading our updates Guys! That is correct we are ALL waiting patiently for the same stock exchange approval process.

Not sure how many...
Show more
2 months ago
loader
loader
Attachment
Alvin Kline Who would be nice to see some trading going on won't be long I'm going to be in granite City I hope it don't take that long 2 weeks ago
loader
loader
Attachment
Alvin Kline Well for waiting for the government to get anything done we're in big trouble because they don't even know who the hell the president is yet 1 week ago
loader
loader
Attachment

Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"

HARVARD Award Winning 
CANCER Killing Success





1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

Frontiers_1.JPG


2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.

 Frontiers_2.JPG


*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

WhatsApp_Image_2022-05-21_at_9.37.37_AM_3.jpg
Skin Cancer 

WhatsApp_Image_2022-05-21_at_9.37.38_AM.jpeg
Karposis Sarcoma

WhatsApp_Image_2022-05-21_at_9.37.38_AM_1.jpeg

CSi Final GIFT Share Issuance Nov 27 2022



Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

 LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

ASU/CSi-EDP-ECO-System
At it's FINEST !!! 

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.



2023 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2023

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296

Class A Common Stock
Authorized:
100,000,000
Issued:
0

Class B Common Stock
Authorized:
1,500,000,000
Issued:
0

Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000



Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE




*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!

 

Events

Sorry, we currently have no events.
View All Events